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Abstract: This paper describes the development of a biosensor based on label-free 
immunosensing for the detection of the C-terminal telopeptide bone turnover marker from 
type-1 collagen. A self-assembled monolayer (SAM) of dithiodipropionic acid was 
deposited on a gold electrode. Then streptavidin and biotinylated anti-human C-terminal 
telopeptide antibody were successively conjugated on the self-assembled monolayer. 
Electrochemical impedance measurements were made to characterize each step of the 
SAM/streptavidin/biotinylated antibody binding. Subsequently, electrochemical impedance 
was measured with different concentrations of C-teminal telopeptide. A detection limit of 
50 ng/mL and a dynamic range up to 3 g/mL were achieved. To our knowledge, this is 
the first attempt to develop a label-free immunosensor based on electrochemical 
impedance with DC bias for detection of bone-related degradation and rebuilding products. 
The electronic biosensor might eventually be used for quantitative point-of-care screening 
of bone health. It is hoped that analysis of bone turnover markers can indicate the 
beginning of bone diseases such as osteoarthritis and osteoporosis so that treatment might 
start early when it is most effective. 
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1. Introduction 
As a living tissue, the health of bone is characterized by how well the cellular mechanism adapts the 
bone to external loading through the modeling and remodeling processes. Both modeling and 
remodeling processes modify the size, shape, and internal micro and macro architecture of bone 
thereby directly influencing bone’s mechanical structural integrity and its strength [1,2].  
Bone turnover markers are useful in understanding bone physiology and assessing the action of 
medications [3,4]. Bone markers can also be used to assess fracture risk and to determine the response 
of bone to treatment. Bone turnover markers actually reflect the metabolic activity of bone during the 
modeling and remolding phases [5–7]. Biochemical bone markers reflecting remodeling include 
resorption markers such as collagen cross-links, while alkaline phosphatase is an example of a marker 
of bone formation [3,8]. Among several bone turnover markers reported in the literature [9,10], 
collagen is the main extracellular protein in the body and forms more than 25% of bone by volume. 
Collagen also constitutes 65% of the total organic component of bone tissue and is thus a good marker 
to study bone health [5]. During the remodeling of bone matrix throughout the skeleton, type I 
collagen is degraded and small peptide fragments are secreted into the blood stream [11]. In addition, 
pyridinium cross-link, cross-linked N-terminal telopeptides of type I collagen, and C-terminal 
telopeptides of type I collagen are released into urine [6]. Antibody is commercially available that is 
specific for the -isomerized amino acid sequence (EKAHD--GGR) found in the C-terminal 
telopeptides of the 1 chain of type I collagen. Based on a previous electronic biosensor [12], a  
label-free electrochemical immunosensor for the detection of bone-related degradation products of  
C-terminal telopeptides from Type-1 collagen was developed and reported in this paper.  
Bone turnover markers are currently under study as a clinical research tool, but they are not 
measured frequently in the same patient. Part of the problem is that they vary across the day and from 
day to day, so some way of integrating the levels might improve their utility. Presently, most methods 
to detect bone turnover markers are based on the enzyme-linked immunosorbent assay (ELISA) [11]. 
This method is time consuming, expensive, and consists of several steps including a staining procedure 
with secondary antibody and fluorescence measurement. In order to carry out a comprehensive study 
of patients to identify the metabolism of bone turnover [12–19], it would be useful to have an 
electrochemical biosensor as a point-of-care device that can quantitate several bone turnover markers 
at a relatively low cost. The objective of this paper is therefore to develop an electronic label-free 
biosensor based on electrochemical impedance spectroscopy (EIS) for the detection of bone turnover 
markers. The advantage of EIS sensing is label-free operation which does not need any secondary 
labeling method. EIS can be also used for multiple protein detection in real time. Besides specific 
proteins [12,14,15], DNA sequences [13] can also be detected using EIS. Even live-cell activity such 
as adhesion and proliferation was measured using EIS [16,17]. Recently aptamer [20] and peptide 
nucleic acids (PNA) [21] were immobilized on an electrode surface for the detection of a specific 
protein, or real time multiple markers [22–24] which increased sensitivity and lowered the detection 
limit. The EIS sensing approach described herein is generic and can be applied to many different bone 
markers by using different antibodies. 
The electronic biosensor might provide additional information about bone turnover markers such as 
marker sensitivity and specificity useful for monitoring patients with certain bone diseases such as Sensors 2009, 9                  
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osteoporosis [30–34]. For example, bone turnover markers can be used monitor treatment [26–30] and 
improve patient persistence with therapy [31]. In addition, these markers are independent predictors of 
fracture risk [26] even though bone mineral density (BMD) assessment is still a major way [25].  
 
2. Experimental Setup  
 
2.1. Reagents and Materials  
 
Biotinylated antibody and antigen (Serum CrossLaps ELISA kit) were purchased from Nordic 
Bioscience Diagnostics. Streptavidin was purchased from BD Pharmingen. All chemical reagents 
including K3Fe(CN)6, K4Fe(CN)6, and KNO3 were purchased from Sigma-Aldrich and prepared fresh 
daily in deionized water. Two different lengths of thiols and sulfides, 3,3-dithiodipropionic acid and 
16-mercaptoundecanoic acid bearing carboxylic acid terminals were obtained from Sigma Aldrich. 
1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) and N-hydroxy-
sulfosuccinimide (Sulfo-NHS) were purchased from Pierce Biotechnology. 
 
2.2. Instrumentation  
 
In order to evaluate the electrochemical properties of electrodes, cyclic voltammetry (CV) and 
electrochemical impedance spectroscopy (EIS) were performed using three-electrode cells, with a gold 
electrode as the working electrode, an Ag/AgCl reference electrode, and a platinum wire counter 
electrode. CV was carried out using a Bioanalytical systems (BAS) analyzer operated with the Epsilon 
system including a C3 cell stand in a Faraday cage. EIS measurements were performed using a Gamry 
Potentiostat (Model: PCI4/750) coupled with EIS (Gamry, EIS300) software. 
 
2.3. Gold Electrode Preparation and Antibody Immobilization 
 
Gold electrodes were prepared using a routine photolithography method. First, 
hexamethyldisilazane (HMDS) was spin-coated on Si/SiO2 wafers. Then photoresist (S1818, Shipley 
Company, MA) was spin-coated on the wafer and soft-baked for 60 seconds at 115 °C. A shadow 
mask was used to selectively irradiate the photoresist with UV light for transferring the electrode 
design. A solitec mask aligner was used to align the optical path and expose the photoresist for 
7 seconds. The wafers were then placed in developing solution and rinsed in deionized (DI) water. 
Gold (0.5 micron) was evaporated onto the patterned substrates using a Temescal FC1800 E-Beam 
Evaporator. A lift-off procedure was performed to remove the photoresist by soaking in acetone. SU-8 
photoresist was spun on the pattern and soft-baked for use as an electrical insulator. Conducting epoxy 
was used to connect electrical wires to the gold electrode. SU-8 photolithography was used to insulate 
the whole area except the 1 mm diameter gold circle and square electrode. The final electrode was 
treated with oxygen plasma to clean the surface.  
The gold electrodes were again cleaned with piranha solution for 30 seconds and rinsed with 
ethanol successively and dried with a stream of nitrogen. The cleaned electrodes were placed in 
ethanol solution with 5 mM of dithiodipropionic acid and 16-mercaptoundecanoic acid overnight to Sensors 2009, 9                  
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form a self-assembled monolayer (SAM). Then electrodes were rinsed with ethanol in order to remove 
non-bonded thiols. The thiol functionalized electrodes were immersed in 0.5 mM of EDC and 0.1 mM 
of sulfo-NHS in pH 6.0 MES buffer solution successively to convert the terminal carboxylic groups to 
an active NHS ester. After rinsing the electrodes with DI water, the activated electrodes were 
immersed in 10 μg/mL of streptavidin in 10 mM of 7.4 pH, Phosphate Buffer Saline (PBS). After 
washing the electrodes to remove excess streptavidin, the electrodes were dipped in 10 μg/mL of 
biotinylated antibody in PBS solution for 4 hours. Then, after rinsing the antibody-modified electrodes 
in PBS, the antibody-electrodes were blocked using 1% bovine serum albumin (BSA) for 30 min to 
minimize non-specific binding sites. After washing the antibody modified electrodes in PBS, the 
electrodes were dipped into the different concentrations of antigen solution for electrochemical 
measurements. Immobilization of antibody and antigen was checked by using fluorescent labeled 
antibody. Another technique such as surface plasmon resonance (SPR) should be used in the future to 
enhance this check. Figure 1 is a schematic representation of the construction and operation of the 
label-free immunosensor for bone maker detection. 
Figure 1. Schematic representation of a label-free immunosensor for bone maker 
detection. Part (A) shows a self-assembled monolayer of dithiodipropionic acid deposited 
on a gold surface with streptavidin immobilized next as a self-assembled monolayer. Then 
the biotinylated antibody was bound to the streptavidin. Part (B) illustrates the antigen-
antibody binding event and how it hinders the interfacial electron transfer reaction of 
[Fe(CN)6]
3−/4−. 
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3. Results and Discussion 
 
Figure 2 illustrates that different size of gold electrode arrays are fabricated using typical 
lithography techniques. Impedance measurement of a cleaned gold electrode was performed at 0.2 V 
over a frequency range between 0.1 Hz and 300 kHz. As shown in Figure 3(a), the overall EIS 
impedance is less than 1 K and a well defined semi-circle was obtained. This experimental result was 
fit to Randle’s equivalent circuit (Figure 3 Inset). The final curve-fit theoretical data in curve b 
matched well with curve a. These data are used as the baseline for further EIS study of the   
antibody-antigen binding complex.  
Figure 2. Optical picture of gold array electrodes which were patterned by a lithography 
technique. 
Gold electrode 
Contacting pad
Gold electrode 
Contacting pad  
Figure 3. Electrochemical impedance spectra for a cleaned gold electrode at 0.2 V over a 
frequency range between 0.1 Hz and 300 kHz. The sinusoidal potential magnitude is   
20 mV in 5.0 mM K3Fe(CN)6 and 5.0 mM of K4Fe(CN)6 in PBS (pH 7.0). The inset is an 
equivalent circuit model used to fit the experimental data. Cdl, is the double layer 
capacitance; Ret, is the electron transfer resistance; W, is Warburg impedance; and Rs, is the 
solution resistance. The final curve-fit theoretical data in curve b matched well with curve a. 
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Figure 4. Three dimensional electrochemical impedance spectra of: (A) a self-assembled 
monolayer with carboxylic terminals on a gold electrode; and (B) a streptavidin 
immobilized electrode. EIS was done at DC potentials from 0 V to 0.5 V with frequencies 
between 0.1 Hz and 300 KHz. The sinusoidal potential magnitude was 20 mV in 5.0 mM 
K3Fe(CN)6 and 5.0 mM of K4Fe(CN)6 in PBS (pH 7.0). 
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Figure 4(A) shows the three dimensional EIS of the self-assembled monolayer of the carboxylic-
terminated group on the gold surface in PBS with 5.0 mM K3Fe(CN)6 and 5.0 mM of K4Fe(CN)6. 
Impedance semi-circles occurred from 0.15 to 0.25 V DC potential, which represents the electron 
transfer resistance. In fact, the smallest semi-circle (lowest impedance) was found at 0.2 V DC for 
redox cycling of 5.0 mM K3Fe(CN)6 and 5.0 mM of K4Fe(CN)6. After immobilizing streptavidin on 
the carboxylic-terminated group on a gold electrode, the semi-circle diameter increased corresponding 
to higher electron transfer resistance as shown in Figure 4(B). The change in electron transfer 
resistance between Figure 4(A) and Figure 4(B) with the DC potential was calculated and the EIS at 
0.2 V showed the largest change. Also, the three dimensional EIS was done more than 40 times and 
the change in electron transfer resistance between the self-assembled monolayer and streptavidin 
immobilized on the gold electrode was repeatable with less then 5% deviation for the 0.2 V DC 
potential. On the other hand, it was difficult to obtain repeatability above a 0.3 V DC potential. The 3-D 
plot provides general results for the whole range of voltage and shows how impedance changes with 
different DC potential. Thus, EIS was carried out at 0.2 V DC potential for the rest of the experiments.  
Next, binding of the biotinylated anti-human C-terminal telopeptide antibody was done for different 
incubation times using a constant concentration, 10 μg/mL of antibody. In Figure 5, the influence of 
biotinylated antibody incubation time on EIS response shows that the electron transfer resistance 
gradually increases with the incubation time up to 4 hours. The increasing electron transfer resistance 
with time indicates that more biotinylated antibody is binding on the streptavidin on the gold electrode. 
Figure 5 shows that binding of the biotinylated antibody is dominant for the first two hours of 
incubation time. Thus the electrode was incubated with antibody for two hours for the subsequent 
antigen detection experiments. In this experiment the electrode became saturated with incubation time. 
Especially important is that there was no increase in circle diameter after 24 hours incubation. In this 
experiment, we did not stir the solution during antibody incubation which might be the reason the 
circle diameter increased gradually until a steady-state value was reached. 
(A)  (B)Sensors 2009, 9                  
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Figure 5. Electrochemical impedance spectra response recorded for the biotinylated   
anti-human C-terminal telopeptides antibody with the incubation time of one-half (a), one 
(b), two (c), four (d), and 24 hours (e). EIS was done at a DC potential of 0.2 V with 
frequencies between 0.1Hz and 300 KHz. The sinusoidal potential magnitude is 20 mV in 
5.0 mM K3Fe(CN)6 and 5.0 mM of K4Fe(CN)6 with PBS (pH 7.0). 
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Figure 6. Electrochemical impedance spectra response recorded at the biotinylated anti-
human C-terminal telopeptide antibody modified electrode in the presence of increasing 
concentration of human C-terminal telopeptide: 0 (a), 0.2 (b), 0.5 (c), 1(d), and 10 (e) μg/mL 
concentration of antigen. EIS was done at a DC potential of 0.2 V at frequencies between 
0.1 Hz and 300 KHz. The sinusoidal potential magnitude was 20 mV in 5.0 mM 
K3Fe(CN)6 and 5.0 mM of K4Fe(CN)6 in PBS (pH 7.0). 
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The procedure for the antigen detection experiment is to: (i) incubate the biotinylated antibody on 
the streptavidin functionalized electrode; (ii) apply antigen to the solution; (iii) incubate for 4 hours; 
(iv) wash the electrode with PBS to remove excess antigen; and (v) measure the EIS. This procedure 
was repeated for different concentrations of antigen. Figure 6 shows the EIS spectra of the 
(a) (b)
(d)(e) (c)
(a) (b)
(d)
(e)
(c)Sensors 2009, 9                  
 
 
7964
immunosensor response recorded at the biotinylated antibody with the increase of C-terminal 
telopeptide (antigen) concentration. In Figure 6, the diameter of the semicircle, and hence the 
corresponding electron transfer resistance, was observed to increase with increasing concentration   
of antigen.  
As shown in Figure 6, the electron transfer of the redox couple was impeded by antigen binding on 
the electrode surface. In such an experiment, a redox reaction with electron transfer kinetics as the 
rate-determining step will display a semicircular feature in an impedance plot of the imaginary 
component of impedance (Zimage) versus the real component of impedance (Zreal) over a frequency 
range. The diameter of the semicircle corresponds to the electron transfer resistance, Ret. Figure 6 
shows the sequential impedance plots obtained after antigen binding occurred at the antibody modified 
electrode. In this Figure, the diameters of the respective semicircles were observed to increase, 
indicating an increasing electron transfer resistance for the [Fe(CN)6]
3−/4− redox reaction following the 
increase of antigen concentration. The EIS results can be simplified to a typical Randle’s circuit model 
without the Warburg impedance term shown in the inset of Figure 3. Randle’s circuit is an equivalent 
circuit representing each component at the interface and in the solution during an electrochemical 
reaction for comparison with the physical components; Cdl, which is the double layer capacitor; Ret, the 
electron transfer resistance; and Rs, the solution resistance. Randle’s circuit can be expressed as: 
imag real
dl et
dl et
dl et
et
et jZ Z
C R
C R j
C R
R
R Z  



 
2 2 2
2
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(1)
Based on the equivalent circuit model, simulated impedance plots were generated to fit the 
experimental results shown as red lines in Figure 6. Acceptable curve fits were obtained using the 
parameters shown in Table 1. Among the three parameters, Rs is a property of the electrolyte solution 
and the distance between the working and reference electrodes, and is not affected much by the 
interfacial kinetics on the electrode’s surface. On the other hand, Cdl and Ret are interfacial properties 
of the electrode/electrolyte and are affected by an insulating layer or a coating on the surface of the 
electrode. As shown in Table 1, there is a more significant change in Ret than in Cdl. Therefore, the 
electron transfer resistance is chosen as the parameter to quantify the immunosensor response due to 
different analyate concentrations. 
Table 1. Estimated parameters for the equivalent circuit model of the immunosensor. 
  Ret [K] Cdl [μF] Rs [] 
Figure 3 (a)  0.23  0.415  170 
Figure 6 (a)  1.25  0.443  172 
Figure 6 (b)  1.51  0.441  173 
Figure 6 (c)  1.78  0.434  173 
Figure 6 (d)  2.78  0.445  174 
Figure 6 (e)  4.10  0.452  173 
 
Figure 7 shows the relationship between the change in electron transfer resistance and the 
concentration of antigen. The calibration curve shows a linear response up to 3 g/mL and the results 
were repeatable within a 10% standard deviation. Sensors 2009, 9                  
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Figure 7. The relationship between the change in electron transfer resistance and the 
concentration of C-terminal telopeptide antigen. 
 
 
Fluorescence microscopy using secondary antibodies was used to visualize the antigen-binding on 
the antibody-immobilized surface. As shown in Figure 8, there was no fluorescence on the antibody-
coated electrode; however, the antigen incubated electrode showed bright fluorescence on the circle, 
and there was also auto-fluorescence on the SU-8 polymer. Figure 9 shows the cyclic voltammetry of 
5.0 mM K3Fe(CN)6 and 5.0 mM of K4Fe(CN)6 in PBS (pH 7.0) with a 100 mV/s scan rate. With the 
immobilization of biotinylated anti-human C-terminal telopeptide antibody and C-terminal telopeptide 
antigen, the current slightly decreased. Blocking the electron transfer by antibody and antigen probably 
causes the decreasing current.  
Figure 8. Fluorescence image of gold electrodes; (a) a gold electrode is coated with 
antibody and (b) a gold electrode is coated with antibody/antigen/fluorescence dye. 
(a) (b)
(a) (b)
SU-8
Wire
Gold electrode 
(a) (b)
(a) (b)
SU-8
Wire
Gold electrode 
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Figure 9. Cyclic voltammetry of 5.0 mM K3Fe(CN)6 and 5.0 mM of K4Fe(CN)6 in PBS 
(pH 7.0) with a 100 mV/s scan rate for: (a) the bare gold electrode; (b) the biotinylated 
anti-human  C-terminal telopeptide antibody immobilized on the electrode after 
functionalizing with 3,3-dithiodipropionic acid; and (c) with 10 μg/mL human C-terminal 
telopeptide antigen in the solution. 
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Repeatable results were obtained by normalizing the response of the sensor by the response of the 
sensor before binding. A detection limit of 50 ng/mL and a dynamic range up to 3 g/mL range were 
obtained. Peichl et al. reported that C-terminal telopeptide concentrations are from 400 to   
20,000 pmol/L in serum and from 30 to 1,400 g/ mmol creatinine in urine. Thus, the suggested 
impedance sensor can cover the physiological levels of collagen C-terminal telopeptide. This type of 
immunosensor might be useful for rapid detection of bone markers. Optimizing the electrode size and 
improving the preparation of the surface of the electrode is expected to lower the detection limit 
dramatically. For future work, we are considering studying the sensitivity of the sensor in the presence 
of interfering materials such as EDTA, ascorbic acid, and other proteins that may cause non-specific 
binding. Simultaneous recording of multiple bone turnover markers at frequent time intervals would be 
possible with a multi-electrode electronic biosensor and this has not been practical in the past.  
Other potentiodynamic methods are also good candidates for bone marker sensors. However 
amperometric detection often needs a secondary label and interference is another problem. 
Electrochemical impedance spectroscopy (EIS) is the complex measure of resistance, capacitance, and 
diffusion over a frequency range from 0.1 Hz to 100KHz. EIS usually provides more information and 
better sensitivity than individual component measurement or low frequency measurement techniques. 
Comparison of EIS with other potentiodynamic methods such as pulsed amperometric detection could 
be the subject of another paper. 
4. Conclusions  
We demonstrated a label-free immunosensor for the detection of bone-related degradation products 
of C-terminal telopeptides of type-1 collagen based on an electrochemical impedance method. There is Sensors 2009, 9                  
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a potential to increase the sensitivity by improving the preparation of the surface of the electrode and 
optimization of the electrode size. To our knowledge, this is the first attempt to develop a label-free 
immunosensor for the detection of bone-related degradation products, which might provide a 
quantitative point-of-care model to screen bone health and identify individual patients early who may 
be prone to osteoporosis. Compared to the ELISA commercial method, which has additional steps 
including secondary antibody immobilization with fluorescence dyes and further complex optical 
measurement, the suggested electronic sensor needs only one step (incubation) from the point of view 
of customers since the commercial biosensor would contain antibody-modified electrodes. Thus 
doctors or even patients can add the sample to the electrode as a point-of-care device and measure the 
electrical signal in 4 hours. Moreover, the electronic sensor can measure the concentration over a 
period of time whereas a single ELISA test cannot. 
New information provided by the proposed biosensor may help to understand and predict bone 
disease. A measurement or “profile” for a patient might be done every 3–6 months at first and 
eventually less often. Clinical trials monitoring multiple bone markers simultaneously would help to 
understand the significance of changes in the bone markers over time and to establish a realistic 
measurement profile.  
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